TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04477109

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: low level laser in addition to diet recommendations
Description: The laser consists of a semiconductor and operates at a wavelength of 650 nanometre. The laser installed in the watch comprises 10 individual laser beams for the wrist and an additional adapter for nasal stimulation. The output power is 5 megawatt

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham laser application in addition to diet recommendations
Description: sham laser application in addition to diet recommendations
Study: NCT00796042

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Subjects will be encouraged to implement the standard wound care protocol that is consistent with the National (CAWC) and Provincial (RNAO) best practice guidelines for the treatment of pressures ulcers. This wound care program will be customized to subject's needs based on the results of the assessment performed by the wound care specialist. A registered dietitian will review blood values associated with nutritional status and make recommendations for dietary changes. Wherever possible, implementation of this wound care program will be coordinated with the subjects' current health care team and appropriate referrals to home care agencies or specialists will be initiated where needed. Subjects assigned to this group will continue their current level of activity (bed rest). Any equipment or services will be obtained through the usual provider agencies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pressure management and Mobility program
Description: Subjects are provided with the same customized wound care program as the usual care group and a pressure management and mobility program that is customized to the individual's needs. This program is based on an in depth home assessment performed by a registered Occupational (OT) or Physical Therapist (PT). Pressure Management Program: A qualified OT or PT will examine the subject on all in-use surfaces and observe all transfers to identify sources of friction and shear, and any strength or balance deficits, identifying what equipment/services are required to manage pressure, improve mobility, and reduce friction and shear. Mobility Program: A qualified PT will assess strength, balance, range of motion, and functional independence with transfers and other ADLs and will develop a mobility program to optimize functional independence and improve strength and balance required for safe and effective transfers. Program to be implemented within one month of this evaluation.
Study: NCT03279341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol
Description: osmotic laxative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl
Description: stimulant laxative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: prokinetic
Study: NCT01283997

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: 200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
Study: NCT05568056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visualizing and Verbalizing for Language comprehension and Thinking
Description: The V/V intervention program is a language remediation program designed by Dr. Nanci Bell, and developed by the Lindamood-Bell Learning Processes (LBLP) (Bell, 1991b). It has been widely used among children with reading disorders, but not with children with ASD. This intervention is based on the use of nonverbal sensory input, in the form of imaged gestalts, in order to develop oral and written language comprehension, establish vocabulary, and develop higher order thinking skills (Bell, 1991a,b).
Study: NCT05581706

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Place the freshly prepared calcium hydroxide in to the root canals
Description: Calcium hydroxide (Merck, Darmstadt, Germany): prepared by mixing with sterile distilled water and then placed in the coronal 1/3 of the root canals.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Place the freshly prepared double antibiotic paste in to the root canals
Description: Double antibiotic paste (DAP): metronidazole (Flagyl, Sanofi-Aventis, Turkey) and ciprofloxacin (Cipro, Biofarma, Turkey) powdered antibiotics were stored and sealed in airtight containers. The same amount of each drug powder (1:1) was mixed and the mixed samples were combined with sterile distilled water to form an ointment. DAP was introduced in roots canals using a lentulo to fill the entire root canal space.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Taking standart periapical radiography with film holder
Description: Post-operative periapical radiographs were obtained with Digora Optime SPP system (Soredex Corp., Tuusula, Finland) using intraoral film holders to keep the plates parallel to the long axis of the teeth. A size #2 SPP was used for all exposures. SPPs were exposed with a Gendex Oralix DC dental x-ray unit (Gendex Dental Systems, Milan, Italy) operating at 60 kVp, 7 mA, 0.25 sec. and the plates were scanned immediately after exposure. The clinical and radiographical follow up was performed on 12th months.~Image-J program (version 1.47, National Institutes of Health, Bethesda, MD) with TurboReg plug-in (Biomedical Imaging Group, Swiss Federal Institute of Technology, Lausanne, Switzerland) was used to determine the increase in root length, root width, and radiographic root area at 12th month follow up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sample collection for immunofluorometric assay
Description: Periapical exudate samples were collected at the beginning of the RET and at 14th day. MMP-8 levels were measured by immunofluorometric assay (IFMA). Briefly, two monoclonal MMP-8-specific antibodies, 8708 and 8706 (Oy Medix Biochemica Ab, Espoo, Finland) were used as catching antibody and tracer antibody, respectively. Samples were diluted in enzyme buffer (50 mM Tris-HCl, pH 7.5; 0.2 mM NaCl, 1 mM CaCl2). Twenty microlitres of samples and 80 μl of assay buffer (20 mM Tris-HCl, pH 7.5, 0.5 M NaCl, 5 mM CaCl2, 0.5% BSA, 0.05% sodium azide and 20 mg/l diethylenetriaminepentaacetic acid with 2 μg/ml normal mouse serum) were pipetted into the wells. The tracer antibody was labelled using europium chelate. After adding the enhancement solution, fluorescence was measured using a 1234 Delfia Research Fluorometer (Wallac, Turku, Finland).
Study: NCT02943265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Coordination Strategies
Description: Co-located Care coordinator will use EMR-driven registry to facilitate patient transitions between primary care and oncology care and enhance teamwork through coaching and technical assistance.
Study: NCT03505749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Informed Mindfulness-Based Relapse Prevention
Description: Trauma Informed-Mindfulness-Based Relapse Prevention (TI-MBRP) will be a 4-week intervention integrating trauma intervention approaches based on Cognitive Processing Therapy (CPT) into standard Mindfulness-Based Relapse Prevention (MBRP). TI-MBRP honors the spirit and cognitive-behavioral foundation of MBRP while introducing components of CPT. Each TI-MBRP session will include mindfulness practices that bring awareness to cognitive and behavioral processes of substance abuse, and how substance use may function as a mechanism to cope with trauma symptoms. Clients are trained to observe internal, triggering stimuli without reactively attempting to avoid these experiences through substance use as well as complete exercises that promote cognitive and emotional processing of traumatic events.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: The Treatment as Usual (TAU) group implemented for this trial will be the standard protocol for Mindfulness-Based Relapse Prevention (MBRP). MBRP is a 4-week exposure-based intervention that integrates integrating mindfulness and acceptance-based techniques with cognitive-behavioral approaches and psycho-education to increase awareness of patterns associated with addictive behaviors and individual factors precipitating and maintaining substance use. These skills are also used to train individuals in responding skillfully in high-risk situations associated with use.
Study: NCT03172481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRC-063 oral capsules
Description: Daily dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsules
Description: Daily dose
Study: NCT03270059

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT02214901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2948 BS for oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01837680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Study: NCT02524249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (dextrose)
Study: NCT00539123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral drug and HIV risk reduction counseling (BDRC)
Description: BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: abstinence-contingent buprenorphine (ACB)
Description: Participants achieving heroin abstinence documented by an opioid-negative urine test receive take-home doses of buprenorphine-naloxone, with the number of take-home doses permitted increasing depending on the number of consecutive opioid-negative urine tests. Participants who test positive receive all doses of buprenorphine-naloxone under direct observation in the clinic, using a three-times per week dosing protocol.
Study: NCT03130998

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Knowledge Broker (rKB)
Description: The intervention is the tailored support received by a knowledge broker via technology in Group B. The rKB will: ensure relevant research evidence related to depression and smoking is transferred to the FHTs in ways that are most useful to them; develop capacity for evidence-informed decision-making at each site; and assist sites in translating evidence into local practice. These tasks will be accomplished by an initial 2-hour, virtual visit with each site and regular phone- and email-based check-ins. The specific tasks will be dictated by the needs of each site, and will create opportunity for practitioners to share their experiences with the rKB, learn new evidence, and work with the rKB on how to best implement the evidence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Emails
Description: When a patient is screened as showing depressive symptoms, the practitioner will be prompted to intervene and refer that patient to treatment. The practitioner will receive knowledge broker support to carry out these actions in the form of one email per month for one year. The first email will provide an electronic copy of a Cochrane review (describing the link between smoking and mood) and a short description of the integration of a depression ICP in the STOP portal. The STOP YouTube channel with detailed instructions on how to use the revised portal will be made available. Subsequent communications will be based on general needs identified at baseline and content discussed in the STOP Community of Practice (teleconferences, online forum between STOP practitioners).
Study: NCT03159975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-70 by electroporation
Description: Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-70 by electroporation
Description: Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-70 by electroporation
Description: Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
Study: NCT03666988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3368715
Description: GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3368715
Description: GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3368715
Description: GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3368715
Description: GSK3368715 will be available with dosing strengths of 25 mg, 100 mg and 250 mg to be administered once daily as an oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3368715
Description: GSK3368715 will be available in Immediate release (IR) white film coated tablet with dosing strengths of 50 mg, 100 mg and 250 mg to be administered orally once daily .
Study: NCT01170234

Intervention type: DEVICE
Intervention: NIOX MINO® Airway Inflammation Monitor
Description: We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
Study: NCT02769078

Intervention type: DRUG
Intervention: dabigatran

Intervention type: DRUG
Intervention: rivaroxaban
Study: NCT04369456

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: a blood sample is taken on Covid-19 kidney transplant patients with moderate symptoms
Study: NCT04277624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant - test formulation
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant - test formulation
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant - reference formulation
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fezolinetant - reference formulation
Description: Administered orally
Study: NCT03717623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole pharmacokinetics
Description: Blood samples will be collected on Days 7, 14 and 21 from the onset of Posaconazole prophylactic treatment If significant diarrhoea occurs, additional blood samples will be collected twice weekly until symptoms resolve. All blood samples will be used for Posaconazole pharmacokinetics study.
Study: NCT00971282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adapalen 0.1%
Description: Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil®
Description: Intra-individual (split-face) comparison: Cetaphil® (only one side of the face) will be applied once daily for 4 weeks.~Visits will be conducted weekly for a maximum of 5 visits.
Study: NCT04824014

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 4FMFES-PET
Description: Intravenous 4FMFES injection, followed with PET imaging
Study: NCT03262805

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lanconone
Description: . Lanconone® is a joint pain supplement containing natural herbs such as Shyonak, Ashwagandha, Shunthi, Guggul, Chopchini, Rasna and Shallaki in therapeutic quantities and documented in the ancient scriptures as pain relievers.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose
Study: NCT03110029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efinaconazole 10% Topical Application Solution [JUBLIA]
Description: Topical efinaconazole 10% solution (Jublia)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Efinaconazole 10% Topical Application Solution [JUBLIA]
Description: Topical efinaconazole 10% solution (Jublia)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of Nail Polish
Description: Application of Nail Polish
Study: NCT04698239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LASER MILESMAN 445 NM
Description: Laser application
Study: NCT01189344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: 600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: 600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
Study: NCT02769078

Intervention type: DRUG
Intervention: apixaban
Study: NCT01107639

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Loading dose 400 mg/m2 2h infusion Weekly: 250 mg/m2 1h infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: * Cisplatin 75 mg/m2 1h infusion d1, 22~* Cisplatin 25 mg/m2 1h infusion weekly x5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: * Cisplatin 75 mg/m2 1h infusion d1, 22~* Cisplatin 25 mg/m2 1h infusion weekly x5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: * Docetaxel 75 mg/m2 1h infusion d1, 22~* Docetaxel 20 mg/m2 1/2h infusion weekly x5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: * Docetaxel 75 mg/m2 1h infusion d1, 22~* Docetaxel 20 mg/m2 1/2h infusion weekly x5

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: During the adjuvant phase, all infusions, given every two weeks, will be at a dose of 500mg/m².

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: During the neoadjuvant phase, the first infusion of cetuximab should be at a dose of 400 mg/m² administered over a period of 2 hours and all subsequent infusions, given weekly, should be of 250 mg/m² over a period of 1 hour, unless any infusion related reaction was observed at a previous infusion. (The maximum infusion rate is 10 mg/min, corresponding to 2 mL/min ready-to-use solution.
Study: NCT02769078

Intervention type: DRUG
Intervention: warfarin
Study: NCT04608019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immediate Antibiotics
Description: increase airway clearance/start oral antibiotics right away

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Treatment
Description: increase airway clearance and start oral antibiotics later if symptoms get worse or do not get better
Study: NCT00003873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eniluracil
Description: Given orally
Study: NCT00552071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR 30 MG Injection
Description: Stable dose of 30 mg octreotide LAR, or a dose determined by historical dosing, delivered every 28 days for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR 30 MG Injection
Description: Stable dose of 30 mg octreotide LAR, or a dose determined by historical dosing, delivered every 28 days for 3 months.
Study: NCT01900067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BARRIER® EasyWarm Active Self-Warming Blanket
Study: NCT04937634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: The subject receives conditioning regimen including melphalan as a part of hematopoietic stem cell transplantation. Dosage of melphalan is 50mg/m\^2/day. Infuse Melphalan over 30 minutes.
Study: NCT01096108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard contest (1 month)
Description: Smoking abstinence, 1 prize award (month 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard contest (1 month)
Description: Smoking abstinence, 1 prize award (month 1)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational and Problem-Solving
Description: Counseling phone calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational and Problem-Solving
Description: Counseling phone calls

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Contests
Description: Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended Contests
Description: Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
Study: NCT00638300

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: large pore (FX80) compared to small pore dialyzer (F8HPS)
Description: Effect of pore size

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: large pore (FX80) compared to small pore dialyzer (F8HPS)
Description: Effect of pore size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L
Description: Effect of dialysate bicarbonate concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L
Description: Effect of dialysate bicarbonate concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L
Description: Effect of dialysate calcium concentration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L
Description: Effect of dialysate calcium concentration
Study: NCT00330369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan
Description: Darusentan administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan
Description: Darusentan administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan
Description: Darusentan administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan Placebo
Description: Placebo to match darusentan administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan Placebo
Description: Placebo to match darusentan administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darusentan Placebo
Description: Placebo to match darusentan administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Darusentan Placebo
Description: Placebo to match darusentan administered orally once daily